Posted on
Provention Bio, Inc. (NASDAQ: PRVB)reported that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 10 yes and 7 no on the question, “Does the information provided in the background documents and presentations by the Applicant and FDA show that the benefits of teplizumab outweigh the risks in support of approval to delay clinical type 1 diabetes mellitus?”. The recommendation on safety and efficacy data from the pivotal TN-10 Study in the single 14 day course of teplizumab delayed insulin dependent, disease by a median of atleast two years in presymptomatic patients with Stage 2 type 1 (T1D) compared to placebo. This acknowledges the unmet medical need facing early stage T1D patients.
Are Body Mass Index and Bile Duct Stones linked? - INDIA New England News indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.
E-Mail
New Orleans, LA - A review study led by Maria D. Sanchez-Pino, PhD, an assistant research professor in the departments of Interdisciplinary Oncology and Genetics at LSU Health New Orleans School of Medicine and Stanley S. Scott Cancer Center, advances knowledge about the connection between obesity-associated inflammation and cancer. The researchers suggest that inflammatory cells with immunosuppressive properties may act as a critical biological link between obesity and cancer risk, progression, and metastasis. The paper is published in the June 2021 issue of
Obesity, available here.
Despite evidence showing that obesity increases the risk of cancer progression, efforts are needed to identify the causal relationship between immunosuppressive cells and the response of immunotherapy in patients with obesity.